| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
3 companies
Judy D. Olian is Director at MAT, with reported holdings spanning 3 companies. Judy D. Olian's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $8.3M at current prices.
Our model assigns Judy D. Olian a middling insider score of 58/100, based on 19 past trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of -7.8%.
Judy D. Olian's largest disclosed position is in ARES as Director, worth about $4.1M. The ARES filings lean toward selling, a net 4,137 shares.
Judy D. Olian has 57 Form 4 filings on record from May 2018 to July 2026, across 3 companies: Director at Ares Management (ARES), 2018–2026; Director at United Therapeutics (UTHR), 2021–2026; Director at Mattel (MAT), 2018–2026.
The 76 reported transactions were 25 open-market sales, 20 option exercises, 15 option or other derivative awards and 10 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $60K and 18 sales worth about $13.3M.
The only open-market purchase was 480 shares of ARES at an average $124.43 on February 20, 2026, about $60K.
The largest open-market sale was 10,000 shares of UTHR at an average $258.56 on May 3, 2024, about $2.6M. Twelve months later UTHR was up 12%.
4 of the 11 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 7 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23, 2026 | UTHR United Therapeutics Corporation | Director | Sell10b5-1 | 200 | $530.00 | $106,000.00 | -4.5% | +3.3% | - | |
| Mar 16, 2026 | UTHR United Therapeutics Corporation | Director | Sell10b5-1 | 200 | $535.44 | $107,088.00 | -4.3% | +2.9% | - | |
| Mar 6, 2026 | UTHR United Therapeutics Corporation | Director | Sell10b5-1 | 200 | $510.00 | $102,000.00 | -4.1% | +14.6% | - | |
| Feb 27, 2026 | UTHR United Therapeutics Corporation | Director | Sell10b5-1 | 200 | $509.55 | $101,910.00 | -4.0% | +11.5% | - | |
| Feb 20, 2026 | ARES Ares Management Corporation | Director | Buy | 480 | $124.43 | $59,726.40 | +1.6% | +0.7% | - | |
| Sep 19, 2025 | UTHR United Therapeutics Corp | Director | Sell | 1,800 | $415.43 | $747,767.88 | -26.3% | +21.4% | +18.5% | |
| Nov 11, 2024 | UTHR United Therapeutics Corp | Director | Sell | 1,750 | $412.48 | $721,840.00 | -23.6% | -13.7% | +14.7% | |
| Jun 17, 2024 | UTHR United Therapeutics Corp | Director | Sell | 1,700 | $295.43 | $502,225.39 | -23.3% | +16.1% | -3.4% | |
| Jun 7, 2024 | ARES Ares Management Corp | Director | Sell | 3,417 | $134.00 | $457,864.67 | -11.1% | +6.1% | +30.8% | |
| May 3, 2024 | UTHR United Therapeutics Corp | Director | Sale+OE | 10,000 | $258.56 | $2,585,601.35 | -57.8% | +24.9% | +12.3% |